Wednesday, July 8, 2026

Patent intelligence · US

US 12146150

Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery

granted A61KA61K48/005A61PA61P25/00
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 18
Applicant portfolio 31
Patent details — US 12146150
Jurisdiction
US
Status
granted
Grant date
Nov 19, 2024
Expiration
Nov 14, 2044
Claims
20
CPC classes
A61K, A61K48/005, A61P, A61P25/00
View on Google Patents ↗

Quick answer

US 12146150 (Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery) is held by VOYAGER THERAPEUTICS, INC.. Status: granted. Granted Nov 19, 2024. Expires Nov 14, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
20
CPC classes
A61K, A61K48/005, A61P, A61P25/00

More from VOYAGER THERAPEUTICS, INC.

Related pharmaceutical patents in our USPTO index.

  1. US 12419969

    AAV capsid variants and uses thereof

    VOYAGER THERAPEUTICS, INC. · Expires Sep 18, 2045

    granted
  2. US 12319929

    Compositions and methods for the treatment of Parkinson's disease

    VOYAGER THERAPEUTICS, INC. · Expires May 29, 2045

    granted
  3. US 12305189

    Compositions and methods for delivery of AAV

    VOYAGER THERAPEUTICS, INC. · Expires May 15, 2045

    granted
  4. US 12296025

    AAV capsid variants and uses thereof

    VOYAGER THERAPEUTICS, INC. · Expires May 8, 2045

    granted
  5. US 12291565

    Tau binding compounds

    VOYAGER THERAPEUTICS, INC. · Expires May 1, 2045

    granted
  6. US 12281321

    Frataxin expression constructs having engineered promoters and methods of use thereof

    VOYAGER THERAPEUTICS, INC. · Expires Apr 17, 2045

    granted
  7. US 12252703

    Closed-ended linear duplex DNA for non-viral gene transfer

    VOYAGER THERAPEUTICS, INC. · Expires Mar 13, 2045

    granted

Frequently asked questions

What is US patent 12146150?

US 12146150 (Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery) is held by VOYAGER THERAPEUTICS, INC.. Status: granted. Granted Nov 19, 2024. Expires Nov 14, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12146150?

VOYAGER THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 31 pharmaceutical patents for this assignee.

When does US 12146150 expire?

Our index shows an expiration date of Nov 14, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.